Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

4.765 +0.695 (+17.08%)
Streaming Delayed Price Updated: 3:53 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 98,586
Open 4.060
Bid (Size) 4.690 (100)
Ask (Size) 4.900 (100)
Prev. Close 4.070
Today's Range 4.020 - 5.000
52wk Range 0.4100 - 5.180
Shares Outstanding 17,210,574
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Regains Compliance with Nasdaq
From Purple Biotech Ltd.
Via GlobeNewswire

Performance

YTD
+621.5%
+621.5%
1 Month
+19.4%
+19.4%
3 Month
+633.1%
+633.1%
6 Month
+670.5%
+670.5%
1 Year
+89.8%
+89.8%

More News

Read More
News headline image
Purple Biotech Announces CEO Transition
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Plan to Implement ADS Ratio Change
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Curious about the most active stocks on Wednesday? ↗
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Dow Surges 250 Points; Verizon Posts Mixed Q3 Results ↗
Via Benzinga
Topics Stocks
News headline image
Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug ↗
Via Stocktwits
News headline image
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
From Purple Biotech Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Purple Biotech Ltd. - American Depositary Shares publicly traded?
Yes, Purple Biotech Ltd. - American Depositary Shares is publicly traded.
What exchange does Purple Biotech Ltd. - American Depositary Shares trade on?
Purple Biotech Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Purple Biotech Ltd. - American Depositary Shares?
The ticker symbol for Purple Biotech Ltd. - American Depositary Shares is PPBT on the Nasdaq Stock Market
What is the current price of Purple Biotech Ltd. - American Depositary Shares?
The current price of Purple Biotech Ltd. - American Depositary Shares is 4.765
When was Purple Biotech Ltd. - American Depositary Shares last traded?
The last trade of Purple Biotech Ltd. - American Depositary Shares was at 04/17/26 03:53 PM ET
What is the market capitalization of Purple Biotech Ltd. - American Depositary Shares?
The market capitalization of Purple Biotech Ltd. - American Depositary Shares is 82.01M
How many shares of Purple Biotech Ltd. - American Depositary Shares are outstanding?
Purple Biotech Ltd. - American Depositary Shares has 82M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.